Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Kashiv BioSciences, LLC today announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab).

A medication called omalizumab (often sold as Xolair) has been around for a long time and was used to help deal with asthma.

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global ...

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from ...

The Food and Drug Administration (FDA) has approved Omlyclo ® (omalizumab-igec), the first interchangeable biosimilar to Xolair ® (omalizumab).. Omlyclo, formerly known as CT-P39, is an anti ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

Omalizumab is also considered unique, as it is safe for children as young as 1-year-olds. Currently, there is only one additional FDA-approved treatment for food allergy ...